Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes

Autores
Aguayo Frías, E.T.; Maza Vega, Daniela; Calienni, M.N.; Melillo, Claudia Marisa; Vazquez, D. S.; Alonso, Silvia del Valle; Montanari, Jorge
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Vismodegib, first approved in 2012 for the treatment of basal cell carcinoma, is an inhibitor of the Hedgehog signaling pathway that becomes active in certain tumors. However, its secondary effects after oral administration and systemic distribution are severe. In this study, we loaded vismodegib into conventional liposomes, which are typically unable to penetrate the stratum corneum barrier effectively after topical application. We studied its skin penetration when coadministered with empty ethosomes, aimed at transiently disrupting the skin impermeability. The drug was successfully recovered from the deeper viable epidermal layers in an in vitro model. The preparation method for the liposomal formulation is reproducible and relatively straightforward to scale up. Furthermore, it involves the use of biocompatible lipids, thus avoiding the utilization of potentially risky compounds.
Instituto Multidisciplinario de Biología Celular
Instituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas
Comisión de Investigaciones Científicas de la provincia de Buenos Aires
Materia
Química
Ethosomes
Liposomes
Drug delivery
Vismodegib
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/160423
Acceder
id SEDICI_ab171cee36308fd0a93116a66bcf3a87
oai_identifier_str oai:sedici.unlp.edu.ar:10915/160423
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomesAguayo Frías, E.T.Maza Vega, DanielaCalienni, M.N.Melillo, Claudia MarisaVazquez, D. S.Alonso, Silvia del ValleMontanari, JorgeQuímicaEthosomesLiposomesDrug deliveryVismodegibVismodegib, first approved in 2012 for the treatment of basal cell carcinoma, is an inhibitor of the Hedgehog signaling pathway that becomes active in certain tumors. However, its secondary effects after oral administration and systemic distribution are severe. In this study, we loaded vismodegib into conventional liposomes, which are typically unable to penetrate the stratum corneum barrier effectively after topical application. We studied its skin penetration when coadministered with empty ethosomes, aimed at transiently disrupting the skin impermeability. The drug was successfully recovered from the deeper viable epidermal layers in an in vitro model. The preparation method for the liposomal formulation is reproducible and relatively straightforward to scale up. Furthermore, it involves the use of biocompatible lipids, thus avoiding the utilization of potentially risky compounds.Instituto Multidisciplinario de Biología CelularInstituto de Investigaciones Fisicoquímicas Teóricas y AplicadasComisión de Investigaciones Científicas de la provincia de Buenos Aires2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/160423enginfo:eu-repo/semantics/altIdentifier/issn/2352-9520info:eu-repo/semantics/altIdentifier/doi/10.1016/j.onano.2023.100186info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:42:01Zoai:sedici.unlp.edu.ar:10915/160423Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:42:01.523SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes
title Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes
spellingShingle Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes
Aguayo Frías, E.T.
Química
Ethosomes
Liposomes
Drug delivery
Vismodegib
title_short Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes
title_full Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes
title_fullStr Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes
title_full_unstemmed Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes
title_sort Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes
dc.creator.none.fl_str_mv Aguayo Frías, E.T.
Maza Vega, Daniela
Calienni, M.N.
Melillo, Claudia Marisa
Vazquez, D. S.
Alonso, Silvia del Valle
Montanari, Jorge
author Aguayo Frías, E.T.
author_facet Aguayo Frías, E.T.
Maza Vega, Daniela
Calienni, M.N.
Melillo, Claudia Marisa
Vazquez, D. S.
Alonso, Silvia del Valle
Montanari, Jorge
author_role author
author2 Maza Vega, Daniela
Calienni, M.N.
Melillo, Claudia Marisa
Vazquez, D. S.
Alonso, Silvia del Valle
Montanari, Jorge
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Química
Ethosomes
Liposomes
Drug delivery
Vismodegib
topic Química
Ethosomes
Liposomes
Drug delivery
Vismodegib
dc.description.none.fl_txt_mv Vismodegib, first approved in 2012 for the treatment of basal cell carcinoma, is an inhibitor of the Hedgehog signaling pathway that becomes active in certain tumors. However, its secondary effects after oral administration and systemic distribution are severe. In this study, we loaded vismodegib into conventional liposomes, which are typically unable to penetrate the stratum corneum barrier effectively after topical application. We studied its skin penetration when coadministered with empty ethosomes, aimed at transiently disrupting the skin impermeability. The drug was successfully recovered from the deeper viable epidermal layers in an in vitro model. The preparation method for the liposomal formulation is reproducible and relatively straightforward to scale up. Furthermore, it involves the use of biocompatible lipids, thus avoiding the utilization of potentially risky compounds.
Instituto Multidisciplinario de Biología Celular
Instituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas
Comisión de Investigaciones Científicas de la provincia de Buenos Aires
description Vismodegib, first approved in 2012 for the treatment of basal cell carcinoma, is an inhibitor of the Hedgehog signaling pathway that becomes active in certain tumors. However, its secondary effects after oral administration and systemic distribution are severe. In this study, we loaded vismodegib into conventional liposomes, which are typically unable to penetrate the stratum corneum barrier effectively after topical application. We studied its skin penetration when coadministered with empty ethosomes, aimed at transiently disrupting the skin impermeability. The drug was successfully recovered from the deeper viable epidermal layers in an in vitro model. The preparation method for the liposomal formulation is reproducible and relatively straightforward to scale up. Furthermore, it involves the use of biocompatible lipids, thus avoiding the utilization of potentially risky compounds.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/160423
url http://sedici.unlp.edu.ar/handle/10915/160423
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/2352-9520
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.onano.2023.100186
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1844616290852929536
score 13.070432

Publicaciones similares